10x Genomics (TXG)

• Market cap: $946M
• 1 day: 2.26%
• 5 days: -7.25%
• 1 month: -26.08%
• 3 months: -52.48%
• 6 months: -50.03%
• Year to date: -45.88%
• 1 year: -72.37%
• 5 years: -89.70%
• 10 years: -85.44%
• Sector: Healthcare
• Industry: Health Information Services

About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Employees: 1,306

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

27% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 49

3% more funds holding

Funds holding: 262 [Q3] → 269 (+7) [Q4]

0.33% less ownership

Funds ownership: 98.03% [Q3] → 97.7% (-0.33%) [Q4]

4% less repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 91

31% less call options, than puts

Call options by funds: $1.4M | Put options by funds: $2.02M

36% less capital invested

Capital invested by funds: $2.35B [Q3] → $1.5B (-$853M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 56% upside
• Avg. target: $15.88 107% upside
• High target: $26 239% upside

8 analyst ratings

• positive: 5 63%
• neutral: 3 38%
• negative: 0 0%

Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target	56% upside $12	Overweight Maintained	10 Apr 2025
Citigroup Patrick Donnelly 26% 1-year accuracy 8 / 31 met price target	95% upside $15	Buy Maintained	4 Mar 2025
Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target	239% upside $26	Overweight Maintained	14 Feb 2025
Canaccord Genuity Kyle Mikson 32% 1-year accuracy 9 / 28 met price target	134% upside $18	Buy Maintained	13 Feb 2025
JP Morgan Rachel Vatnsdal 38% 1-year accuracy 6 / 16 met price target	56% upside $12	Neutral Maintained	13 Feb 2025